Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 7/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21617238 | 1.00 | BRD4 (0.47) | BRD4SMOMAPK14GPR132PAX8 | |
| SCHEMBL21617162 | 0.95 | SMO (0.46) | BRD4SMOMAPK14GPR132KCNH2 | |
| SCHEMBL31504407 | 0.95 | SMO (0.46) | BRD4SMOMAPK14GPR132KCNH2 | |
| SCHEMBL21617209 | 0.90 | BRD4 (0.49) | BRD4SMOMAPK14GPR132NR1H4 | |
| SCHEMBL21617180 | 0.86 | NPC1 (0.43) | PAX8NR1H4 | |
| SCHEMBL31504444 | 0.85 | BRD4 (0.44) | BRD4SMOMAPK14GPR132NR1H4 | |
| SCHEMBL21617269 | 0.85 | BRD4 (0.44) | BRD4SMOMAPK14GPR132NR1H4 | |
| SCHEMBL31504320 | 0.85 | SMO (0.46) | BRD4SMOMAPK14GPR132KCNH2 | |
| SCHEMBL21617198 | 0.85 | SMO (0.46) | BRD4SMOMAPK14GPR132KCNH2 | |
| SCHEMBL21617187 | 0.84 | MAPK14 (0.44) | BRD4SMOMAPK14GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638877-B | Phenyl/pyridinyl-N-phenyl/pyridinyl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2025-04-22 | — | — | CN | disclosed |